Publications
-
Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
Hsu JY,
Wakelee HA.
BioDrugs.
2009;
23
(5):
289-304
-
Pemetrexed disodium for the treatment of NSCLC: an update.
Hsu JY,
Wakelee H.
Drugs Today (Barc).
2008;
44
(9):
669-78
-
Oncogenic regulators and substrates of the anaphase promoting complex/cyclosome are frequently overexpressed in malignant tumors.
Lehman NL,
Tibshirani R, Hsu JY, Natkunam Y, Harris BT, West RB, Masek MA, Montgomery K, van de Rijn M, Jackson PK.
Am J Pathol.
2007;
170
(5):
1793-805
-
Overexpression of the anaphase promoting complex/cyclosome inhibitor Emi1 leads to tetraploidy and genomic instability of p53-deficient cells.
Lehman NL,
Verschuren EW, Hsu JY, Cherry AM, Jackson PK.
Cell Cycle.
2006;
5
(14):
1569-73
-
Prophase destruction of Emi1 by the SCF(betaTrCP/Slimb) ubiquitin ligase activates the anaphase promoting complex to allow progression beyond prometaphase.
Margottin-Goguet F,
Hsu JY, Loktev A, Hsieh HM, Reimann JD, Jackson PK.
Dev Cell.
2003;
4
(6):
813-26
-
Control of the centriole and centrosome cycles by ubiquitination enzymes.
Hansen DV,
Hsu JY, Kaiser BK, Jackson PK, Eldridge AG.
Oncogene.
2002;
21
(40):
6209-21
-
E2F-dependent accumulation of hEmi1 regulates S phase entry by inhibiting APC(Cdh1).
Hsu JY,
Reimann JD, Sørensen CS, Lukas J, Jackson PK.
Nat Cell Biol.
2002;
4
(5):
358-66
-
Emi1 is a mitotic regulator that interacts with Cdc20 and inhibits the anaphase promoting complex.
Reimann JD,
Freed E, Hsu JY, Kramer ER, Peters JM, Jackson PK.
Cell.
2001;
105
(5):
645-55
-
The lore of the RINGs: substrate recognition and catalysis by ubiquitin ligases.
Jackson PK,
Eldridge AG, Freed E, Furstenthal L, Hsu JY, Kaiser BK, Reimann JD.
Trends Cell Biol.
2000;
10
(10):
429-39
Help